Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
Department of Pharmaceutics, College of Pharmacy, Jouf University, Sakaka, Kingdom of Saudi Arabia (KSA).
Expert Opin Drug Deliv. 2019 Dec;16(12):1355-1366. doi: 10.1080/17425247.2019.1684895. Epub 2019 Nov 8.
: Intranasal drug delivery is a largely unexplored, promising approach for the treatment of various neurological disorders. However, due to the challenging constraints available in the pathway of nose-to-brain delivery, finding an effective treatment for Parkinsonism is still an impending mission for research workers. This warrants development of novel treatment alternatives for Parkinson's disease (PD). Intranasal delivery of mucoadhesive nanocarriers is one such novel approach which might help in curbing the glitches associated with the currently available therapy.: This review summarizes the evidences supporting nose-to-brain delivery of polymer-based mucoadhesive nanocarriers for the treatment of PD. A concise insight into the lipid-based mucoadhesive nanocarriers has also been presented. The recent researches have been compiled pertaining to the use of mucoadhesive nanocarrriers for improving the treatment outcomes of PD via intranasal drug delivery.: Although the use of nanocarrier-based strategies for site-specific delivery via intranasal route has proven effective, the magnitude of improvement remains moderate resulting in limited translation from industry to the market. Comprehensive understanding of the mucoadhesive polymer, its characteristics and mechanisms involved for an effective nose-to-brain uptake of the drug is a promising avenue to develop novel formulations for effective management of Parkinson disease.
鼻腔内给药是一种尚未得到充分探索的、有前途的治疗各种神经疾病的方法。然而，由于鼻内递送到脑内的途径存在挑战性的限制，为帕金森病找到有效的治疗方法仍然是研究人员面临的一项紧迫任务。这就需要为帕金森病（PD）开发新的治疗选择。鼻腔内递送至黏膜黏附性纳米载体是一种新的方法，可能有助于克服目前可用疗法相关的缺陷。本文综述了支持基于聚合物的黏膜黏附性纳米载体经鼻腔递送至脑内治疗 PD 的证据。还简要介绍了基于脂质的黏膜黏附性纳米载体。已经汇集了有关使用黏膜黏附性纳米载体通过鼻腔内药物递送来改善 PD 治疗效果的最新研究。尽管基于纳米载体的策略已被证明可通过鼻腔途径进行靶向递药，但改善的程度仍然有限，导致从工业到市场的转化有限。全面了解黏膜黏附性聚合物及其特性和机制，以有效吸收药物，是开发用于有效管理帕金森病的新型制剂的有前途的途径。
